Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

2,237 total articles

Euroseas (ESEA): Deep-Value Container Play with Near-Term Catalysts

Euroseas (ESEA): Deep-Value Container Play with Near-Term Catalysts

Euroseas is trading at bargain multiples (P/E 3.3, P/B ~1.0) with a market cap of ~$460M and an upcoming ex-dividend date on 03/10/2026. Recent time charters for fuel-efficient 1,800 TEU feeders at $22k-$24.25k/day and a technically constructive setup support a mid-term long trade. The trade carries cyclical and execution risks; use a clear stop an…

Snowflake: Buying the Pullback to a New Growth Chapter

Snowflake: Buying the Pullback to a New Growth Chapter

Snowflake (SNOW) has pulled back from its 52-week highs but still trades at premium multiples. With a $61.6B market cap, 30% reported revenue growth, and clear AI positioning, the stock offers a tactical long opportunity for investors willing to accept valuation and legal risk. This trade idea lays out entry, stop, targets, catalysts, and the scena…

Tactical Swing: Buy UROY for Royalty Exposure to the Uranium Upswing

Tactical Swing: Buy UROY for Royalty Exposure to the Uranium Upswing

Uranium Royalty Corp. (UROY) offers investors a way to participate in higher uranium prices through a growing royalty portfolio and selective physical holdings. At a market cap of roughly $504.6M and a share price near $3.65, UROY is a leveraged, lower-capex play on the sector. This note lays out a mid-term (45 trading days) swing trade: entry $3.6…

DELIVER Data and Phase-3 Start Put Dyne (DYN) Back on the Biotech Radar

DELIVER Data and Phase-3 Start Put Dyne (DYN) Back on the Biotech Radar

Positive cardiopulmonary results from the DELIVER trial and the initiation of the Phase 3 HARMONIA study for z-basivarsen (DYNE-101) meaningfully de-risk Dyne's clinical story. With shares trading near $17 and market cap around $2.8B, the setup favors a disciplined long swing trade that captures further validation and potential re-rating as late-st…

Tilray Looks Like a Future Winner — For Now Treat It as a Hold

Tilray Looks Like a Future Winner — For Now Treat It as a Hold

Tilray's move into global beverages via the BrewDog asset purchases meaningfully boosts revenue and expands distribution, taking total annualized revenue toward ~$1.2B. Fundamentals and valuation (market cap near $0.8B, P/S ~1, P/B ~0.53) argue the stock is cheap on many metrics, but negative margins, persistent free cash flow losses, and weak tech…

Sea Ltd.: Buy the Post-Earnings Weakness for a 6-Month Recovery Play

Sea Ltd.: Buy the Post-Earnings Weakness for a 6-Month Recovery Play

Sea Limited plunged after Q4 commentary emphasized margin compression and softer Garena bookings despite beats. That sell-off has pushed technicals into oversold territory and trimmed valuation expectations versus the stock's recent highs. This trade idea takes a disciplined long stance: enter after the post-earnings weakness, use a tight structura…

Fade The Run: Short SWBI Into Overbought Exhaustion

Fade The Run: Short SWBI Into Overbought Exhaustion

Smith & Wesson (SWBI) has ripped to a 52-week high but carries weak recent sales momentum, thin profitability, an upcoming ex-dividend, and an overbought technical setup. This trade idea advocates a tactical short for a mean-reversion move back toward the $12 area over the next 10 trading days, with strict risk controls.

Palantir: Positioning for a Multi-Quarter Rebound

Palantir: Positioning for a Multi-Quarter Rebound

<p>Palantir’s sell-off from the $200 area has created a tactical long opportunity. Strong top-line momentum (reported ~70% Q4 growth), an expanding deal pipeline ($8.6B remaining deal value, +91% YoY), improving technicals and light short-covering combine to favor a measured long. That said, valuation is rich and this is a high-risk trade — the pla…

Berkshire Hathaway: Buybacks Resume — Time to Add Exposure

Berkshire Hathaway: Buybacks Resume — Time to Add Exposure

Berkshire Hathaway's new-era management has restarted disciplined buybacks after a 19-month pause under Warren Buffett. At roughly $491, the stock offers an asymmetric setup: attractive valuation metrics (P/E ~16, P/B ~1.5), ongoing FCF generation (~$19.3B), and a multihundred-billion-dollar cash war chest that can be deployed opportunistically. I'…

Buy Best Buy for Rising Long-Term Income and Valuation Re-Rating

Buy Best Buy for Rising Long-Term Income and Valuation Re-Rating

Best Buy (BBY) offers a compelling long-term income opportunity: a 5.7% yield, solid free cash flow of $1.51B, and conservative leverage. With EV/EBITDA at 5.5 and P/FCF ~9.2, the stock looks inexpensive for a retailer that continues to expand services and vendor support. This trade targets dividend capture and upside to $82 over a 180-trading-day …

Buy Abbott for Steady Long-Term Upside After Operational Noise

Buy Abbott for Steady Long-Term Upside After Operational Noise

Abbott (ABT) has had a rough patch in diagnostics and a product-quality hiccup, but the balance sheet, cash generation ($7.4B free cash flow), and valuation metrics leave room for 20%+ upside over the next 6 months if management stabilizes operations and integration of Exact Sciences goes as planned. This trade plan targets entry at $110.00, a $135…